Sigma-Aldrich Names New Sales & Research Biotech Leaders
Van den Dool, who will be responsible for sales for all three of the Company's research business units, joined Sigma-Aldrich in 1999 as the head of European Research Sales. He served in sales leadership roles at both Amersham-Pharmacia and Molecular Dynamics prior to joining the Company and holds degrees in Applied Physics from HTS Dordrecht University and in Business from Tilburg University of Eindhoven, both in the Netherlands. van den Dool will relocate to St. Louis from his current assignment in Munich, Germany, and will report directly to Jai Nagarkatti, President & CEO.
Smoller joined Sigma-Aldrich as Vice President Research & Development in 2004 after founding and selling two successful biotech start-up companies - Genome Systems, Inc. and ProteoPlex, Inc. - over the prior decade. Since joining the Company, he had assumed broader responsibilities as Vice President R&D and Operations for Sigma-Aldrich's Research Biotech business unit and been named to the Company's Key Management Group in late 2005. Smoller, who holds Ph.D. and B.S. degrees in Biology from Emory University and who completed his post doctoral fellowships with Washington University and Monsanto Company, will also report directly to Nagarkatti. Shaf Yousaf, the previous President of the Research Biotech business unit, has left the Company to pursue other interests.
In a related move, Gilles Cottier, President of the Company's Research Essentials business unit and a member of its Executive Management Group, will add direct oversight of operations in India and China - two of the Company's most rapidly growing markets - to his existing duties.
Most read news
Topics
Organizations
Other news from the department people
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.